Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Galera Therapeutics, Inc. (GRTX : OTC)

• Company Description    Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel, proprietary therapeutics to transform radiotherapy in cancer. The company's product candidate is GC4419, a highly selective and potent small molecule dismutase mimetic which is designed to rapidly convert superoxide to hydrogen peroxide. Galera Therapeutics, Inc. is headquartered in Malvern, PA. Number of Employees: 3

• Price / Volume Information    Yesterday's Closing Price: $0.03 Daily Weekly Monthly 20 Day Moving Average: 47,414 shares Shares Outstanding: 75.46 (millions) Market Capitalization: $2.15 (millions) Beta: 1.87 52 Week High: $0.15 52 Week Low: $0.02 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 14.46% 9.61% 12 Week 14.00% -6.30% Year To Date -37.77% -40.71%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 101 LINDENWOOD DRIVE SUITE 225 - MALVERN,PA 19355 USA ph: 610-725-1500 fax: - jsussman@galeratx.com http://www.galeratx.com

• General Corporate Information    Officers J. Mel Sorensen - Chief Executive Officer; President and Chairman of Joel Sussman - Chief Accounting Officer Lawrence Alleva - Director Kevin Lokay - Director Michael Friedman - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 36338D108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 75.46 Most Recent Split Date: (:1) Beta: 1.87 Market Capitalization: $2.15 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 87.50% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/25 - - 12/31/24 - - 09/30/24 - - ROA 03/31/25 - -123.91 12/31/24 - -123.53 09/30/24 - -99.34 Current Ratio 03/31/25 - 7.75 12/31/24 - 6.00 09/30/24 - 9.74 Quick Ratio 03/31/25 - 7.75 12/31/24 - 6.00 09/30/24 - 9.74 Operating Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Net Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Pre-Tax Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Book Value 03/31/25 - -1.95 12/31/24 - -1.96 09/30/24 - -2.63 Inventory Turnover 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Equity 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Capital 03/31/25 - - 12/31/24 - - 09/30/24 - -

Powered by Zacks Investment Research ©